Research programme: peptide therapeutics - Lee's Pharmaceutical

Drug Profile

Research programme: peptide therapeutics - Lee's Pharmaceutical

Alternative Names: Papain - Lee's Pharmaceutical; Thymosin beta-4 - Lee's Pharmaceutical; ZK003; ZK004; ZK005

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Peptides
  • Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye-Disorders
  • No development reported Alopecia; Vulvovaginal candidiasis
  • Discontinued Hypertrophic scars

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia(Chemotherapy-induced) in China
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vulvovaginal-candidiasis in China
  • 17 Aug 2015 Lee's Pharmaceuticals files an IND application in China for chemotherapy-induced alopecia (Dermatology on the Company pipeline, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top